I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ADPD 2024

-
Coming soon
03:00 PM
Duration 24hrs Lisbon, Portugal
Modeling of Parkinson’s disease progression and impact of endpoint selection on probability of study success
Benjamin Ribba

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 24hrs Lisbon, Portugal
Poster: Slower progression of digital acoustic speech measures in early Parkinson’s Disease under prasinezumab during the first 52 weeks of the PASADENA study
Damian Kwasny

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 24hrs Lisbon, Portugal
Audio Recording: Slower progression of digital acoustic speech measures in early Parkinson’s Disease under prasinezumab during the first 52 weeks of the PASADENA study
Damian Kwasny

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:00 AM
Duration 15mins Virtual
Oral Presentation: Slower progression of digital acoustic speech measures in early Parkinson’s Disease under prasinezumab during the first 52 weeks of the PASADENA study
Damian Kwasny

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:45 PM
Duration 15mins Auditorium VIII
PASADENA long-term open-label extension continue to show reduced motor and functional progression in prasinezumab-treated individuals with early-stage Parkinson’s disease compared to a real-world data arm
Gennaro Pagano

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:20 PM
Duration 15mins Auditorium VI+VII
Performance of blood-based biomarker prescreening in the SKYLINE secondary prevention phase 3 study with gantenerumab
Tobias Bittner

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:00 AM
Duration 24hrs Lisbon, Portugal
SAMPLE STABILITY STUDY FOR THE ELECSYS® CSF II IMMUNOASSAYS AT 25 °C, 2-8 °C AND -15 TO -25°C
Manuilova E

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 24hrs Lisbon, Portugal
Cerebrospinal fluid biomarkers of NLRP3 pathway activation, neuroinflammation and neurodegeneration in Parkinson’s Disease: a meta-analysis
Bastian Zinnhardt

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:25 PM
Duration 15mins Auditorium VIII
A phase IIa study investigating a γ-secretase modulator in individuals at risk for or at the prodromal stage of Alzheimer's disease
Rosanna Tortelli

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:25 AM
Duration 15mins Auditorium I
Rapid dose-dependent amyloid plaque depletion with trontinemab, a novel BrainshuttleTM antibody in development for the treatmetn of Alzheimer's disease
Luka Kulic

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:40 PM
Duration 15mins Auditorium VIII
A study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson’s disease (PADOVA): rationale, design and baseline data
Tania Nikolcheva

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:25 PM
Duration 15mins Auditorium VII
CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signatures
Felix L. Yeh

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar